November 23, 2009 (FinancialWire) Becton, Dickinson and Co. (NYSE: BDX) has closed its acquisition of HandyLab, Inc., an Ann Arbor, Michigan-based company that develops and manufactures molecular diagnostic assays and automation platforms.
In May 2009, BD and HandyLab announced an exclusive agreement for BD to develop and commercialize molecular assays on the HandyLab Jaguar platform, an integrated molecular diagnostic system designed to provide hands-off operation, incorporating clinical sample preparation, nucleic acid extraction, and microfluidic real-time polymerase chain reaction amplification and detection in a bench-top system.
The self-contained workstation is designed to accommodate both batch workflows and on-demand testing for maximum lab efficiency and flexibility.
With the acquisition, BD will migrate its BD GeneOhm molecular assays for Methicillin-resistant Staphylococcus aureus, Clostridium difficile and Vancomycin-resistant Enterococcus onto the new platform and will market them as the new BD MAX system, an evolution of the current Jaguar system.
Franklin Lakes, New Jersey-based Becton, Dickinson is a global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. BD employs approximately 29,000 associates in approximately 50 countries throughout the world.
The company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.
FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.
Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).
SADIF Analytics releases new summary due diligence report for Becton, Dickinson and Co. Ilhavo, Portugal – 13/10/2009 – SADIF Investment Analytics, announces a new summary due diligence report covering Becton, Dickinson and Co. (BDX). The report uses SADIF's powerful StockMarks™ stock... |
ALPHAHELIX – Newly Released Company Financials and Credit Information (Published 12th June 2009) http://www.companiesandmarkets.com/Summary-Company-Financials/alphahelix-111005.aspxAlphaHelix Molecular Diagnostics AB is a company that develops, manufactures and markets technology and products for... |
FAB Pharma, a Biopharma Company Developing Drugs to Treat Severe Bacterial Infections, Raises €2.3 Million in Series A Funding .. FAB Pharma today announced the completion of a €2.3 million round of series A funding led by CDC innovation and co-led by Bioam Gestion.FAB Pharma has acquired assets in the treatment of methicillin-resistant... |
Nanosphere To Update Package Insert For Its Respiratory Virus Assay November 27, 2009 (FinancialWire) Nanosphere, Inc. (NASDAQ: NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, has received 510(k) clearance from the... |
Response Genetics, Inc. to Release Second Quarter 2009 Financial Results Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and commercialization of molecular diagnostic tests for cancer, will announce financial results for the second quarter of 2009... |
TwistDx Launches World’s First DNA Amplification Kit Based on Recombinase Polymerase Amplification (RPA) TwistDx, a developer of point-of-use nucleic acid diagnostics, announced today the launch of its TwistAmpTM product range, the world’s first DNA amplification products based on Recombinase Polymerase... |
